Agilent Technologies, a leading supplier of laboratory equipment and analytical instruments, announced Wednesday that it is increasing its full‑year profit guidance. The company now expects an adjusted earnings per share (EPS) of $6.18 to $6.21, up from the prior range of $6.00 to $6.10.
Improving market conditions
CEO Padraig McDonnell said the company is seeing “improving end markets, stronger demand in key regions, and excellent customer response to our innovative product launches.” After a multi‑year downturn driven by constrained biotech funding and uneven demand, U.S. life‑science and laboratory‑equipment firms are beginning to recover.
Quarterly performance
Agilent reported third‑quarter revenue of $1.88 billion, surpassing analysts’ consensus estimate of $1.84 billion. Adjusted profit for the quarter ended July 31 was $1.62 per share, which includes a 6‑cent benefit from tariff refunds, beating the $1.49 per‑share estimate.
Revenue from the CrossLab unit, which provides software and services for laboratory management, grew 6% to $786 million, underscoring the company’s focus on integrated solutions that help customers run more efficient research operations.
Analyst expectations
Industry analysts had projected full‑year revenue of $7.45 billion and an adjusted EPS of $6.06. While the new profit range still falls short of the EPS estimate, the upward revision signals confidence that demand for Agilent’s medical tools, diagnostic platforms, and research instruments will continue to strengthen through the remainder of the fiscal year.
Implications for the sector
The upgraded outlook reflects a broader trend of renewed investment in life‑science research as pharmaceutical companies and academic labs ramp up drug‑development pipelines. Stronger demand for precision instruments and data‑analysis software is expected to support further growth for companies that supply the underlying technology.
Agilent’s performance also highlights the impact of recent tariff refunds, which have helped offset cost pressures for manufacturers that rely on imported components. The company’s ability to translate product innovation into tangible sales growth suggests a resilient business model that can weather macro‑economic fluctuations.
Looking ahead
Management indicated that upcoming product launches and continued expansion of the CrossLab service platform will be key drivers of future revenue. As the biotech funding environment stabilizes, Agilent expects its customers to increase spending on high‑quality analytical tools, reinforcing the company’s position as a critical partner in the life‑science ecosystem.
Investors will be watching the company’s next quarterly results for signs that the upward momentum sustains, particularly as the broader market assesses the health of the biotech sector and related research funding.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
